Search

Industry Examiner
Industry Examiner @IndustryExaminr ·
Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda. When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff. Read: biotech.industryexaminer.com/merck-terns-de… #Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechMandA
Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda - Biotech Industry Examiner

The target is a leukemia drug developer. The real objective is something larger: time, diversification, and a more believable post-Keytruda growth story.

From biotech.industryexaminer.com
7
Business-News-Today.com
Business-News-Today.com @cricket_fundas ·
Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears business-news-today.com/mercks-6-7bn-t… #Merck #MRK #TERN #TernsPharma #CML #ChronicMyeloidLeukemia #TERN701 #Oncology #Hematology #Keytruda #BioPharma #MnA #DrugDevelopment #Scemblix #Novartis #TernsPharmaceuticals
Merck's $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in

Merck agrees to acquire Terns Pharmaceuticals for $6.7B, adding TERN-701 CML drug to its oncology pipeline ahead of Keytruda's 2028 patent cliff. Read the full analysis.

From business-news-today.com
38
sumedico.com
sumedico.com @sumedico ·
Merck podría pagar 6,000 millones de dólares en efectivo por Terns, reforzando oncology y anticipando la expiración de Keytruda. ¿Qué impacto tendrá en pulmones de ingresos? Avance clave para la cartera oncológica. #Merck #Terns #Oncología #Farma sumedico.com/lideres-de-la-…
Merck apuesta 6,000 millones de dólares por Terns

La farmacéutica Merck & Co. está en la fase final para adquirir a Terns Pharmaceuticals por unos 6,000 millones de dólares, en un movimiento para fortalecer su portafolio de productos ante la próxima...

From sumedico.com
45
channelchek
channelchek @channelchek ·
Merck Bets $6.7 Billion on a Former Microcap’s CML Drug — TERN Investors Reap the Reward channelchek.com/news-channel/m… #Merck #CMLDrug #TERN #Biotech #Investing #Channelchek
Merck Bets $6.7 Billion on a Former Microcap's CML Drug — TERN Investors Reap the Reward - Channe...

Merck (NYSE: MRK) announced Tuesday it has entered into a definitive agreement to acquire Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage oncology company, for $53.00 per share in cash —...

From channelchek.com
22
BioPoint Inc.
BioPoint Inc. @biopointinc ·
Merck is buying Terns for $6.7B to strengthen its cancer pipeline ahead of Keytruda’s patent loss. The deal focuses on a leukemia drug that could drive future growth. biospace.com/deals/merck-to… #pharma #biotech #merck #oncology #drugdevelopment
Big fish eats small, takeover of the company. Art collage.
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms

Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiry of its blockbust...

From biospace.com
23
Financial Data Drive
Financial Data Drive @FinDataDrive ·
M&A Alert $MRK deploying $6.7B in cash to acquire $TERN at $53/sh. A statistically significant move to de-risk the 2028 Keytruda patent cliff. Merck is restructuring for an oncology-heavy 2030. 💊📊 #Merck #Biotech #Earnings
78
PharmaShots | Iluminate.Innovate.Inspire
PharmaShots | Iluminate.Innovate.Inspire @Pharmashot ·
Replying to @Merck
@Merck to Acquire @TernsPharma for ~$6.7B #merck #ternspharmaceuticals #acquisition #hematology #tern701 #chronicmyeloidleukemia #pi #pii #cardinal pharmashots.com/32361/merck-to…
Merck to Acquire Terns Pharmaceuticals for ~$6.7B

Shots: Merck has entered into a definitive agreement to acquire Terns, incl. its asset TERN-701 asset, expanding its oncology pipeline As per the deal, Merck will acquire Terns for $53/share in cash,...

From pharmashots.com
13